Statistical issues related to early closure of STOP-ROP, a group-sequential trial

Controlled Clinical Trials

Volumn 24, Issue 1, 2003, Pages 28-38

  Oden, Neal L ^a   Phelps, Dale L ^b  

^a EMMES CORPORATION   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Early termination; Group sequential; Recruitment; Retinopathy of prematurity; Stopping rules

Indexed keywords

OXYGEN;

ARTICLE; CHILD CARE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECISION MAKING; HUMAN; INFANT; METHODOLOGY; ORGANIZATION; OXYGEN THERAPY; PREDICTION; PROFESSIONAL STANDARD; RETROLENTAL FIBROPLASIA; SAFETY; STATISTICS;

CLINICAL TRIALS DATA MONITORING COMMITTEES; DATA INTERPRETATION, STATISTICAL; DISEASE PROGRESSION; HUMANS; INFANT, NEWBORN; OXYGEN INHALATION THERAPY; RANDOMIZED CONTROLLED TRIALS; RETINOPATHY OF PREMATURITY;

EID: 0037306237     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-2456(02)00276-3     Document Type: Article

References (31)

1. Phelps DL, Oden NL, Bradford JD, et al. Supplemental Therapeutic Oxygen for Prethreshold ROP Study (STOP-ROP): manual of procedures. Springfield, Virginia. National Technical Information Service, 1999. Accession no. PB99-172348.
2. STOP-ROP Multicenter Study Group Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity (STOP-ROP), a randomized, controlled trial. I. Primary outcomes Pediatrics. 105:2000;295-310. [with comments].
3. Silverman W.A. Retrolental fibroplasia. a modern parable:1980;Grunn & Stratton, New York.
4. Kinsey V.E., Jacobus J.T., Hemphill F.M. Retrolental fibroplasia. cooperative study of retrolental fibroplasia and the use of oxygen Arch Ophthalmol. 56:1956;481-547.
5. Patz A., Hoeck L., De La Cruz E. Studies on the effect of high oxygen administration in retrolental fibroplasia. I. Nursery observations. Am J Ophthalmol. 35:1952;1248-1252.
6. Cryotherapy for Retinopathy of Prematurity Cooperative Group Multi center trial of cryotherapy for retinopathy of prematurity. three-month outcome Arch Ophthalmol. 108:1990;195-204.
7. Cryotherapy for Retinopathy of Prematurity Cooperative Group Multicenter trial of cryotherapy for retinopathy of prematurity. Snellen visual acuity and structural outcome at 5 1/2 years after randomization Arch Ophthalmol. 114:1996;417-424.
8. Cryotherapy for Retinopathy of Prematurity Cooperative Group Multicenter trial of cryotherapy for retinopathy of prematurity. Ophthalmologic outcomes at 10 years. Arch Ophthalmol. 119:2001;1110-1118.
9. Gaynon MW, Stevenson DK, Sunshine P, Fleischer BE. Supplemental oxygen and light for prethreshold retinopathy of prematurity. In: Shapiro M, Biglan AW, Miller MM, editors. Retinopathy of prematurity. Proceeding of the International Conference on Retinopathy of Prematurity. Chicago, Illinois, Amsterdam/New York: Kugler Publications; 1993:137-138.
10. Szewzyk T. Retrolental fibroplasia and related ocular diseases. classification, etiology, and prophylaxis Am J Ophthalmol. 36:1953;1333-1361.
11. Bedrossian R., Charmichael P., Ritter J. Effect of oxygen weaning in retrolental fibroplasia. Arch Ophthalmol. 53:1955;514-518.
12. Bedrossian R., Carmichael P., Ritter J. Retinopathy of prematurity (retrolental fibroplasia) and oxygen. Part I. Clinical study. Part II. Further observations of the disease Am J Ophthalmol. 37:1954;78-86.
13. Chan-Ling T., Gock B., Stone J. Supplemental oxygen therapy. Basis for noninvasive treatment of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 36:1995;1215-1230.
14. Phelps D.L., Rosenbaum A.L. Effects of marginal hypoxemia on recovery from oxygen-induced retinopathy in the kitten model. Pediatrics. 73:1984;1-6.
15. Phelps D.L. Reduced severity of oxygen-induced retinopathy in kittens recovered in 28% oxygen. Pediatr Res. 24:1988;106-109.
16. Wei L.J., Lachin J.M. Properties of the urn randomization in clinical trials. Control Clin Trials. 9:1988;354-364.
17. Lan K.K.G., DeMets D.L. Discrete sequential boundaries for clinical trials. Biometrika. 70:1983;659-663.
18. Reboussin DM, DeMets DL, Kim K, Lan GGK. Programs for computing group sequential bounds using the Lan-DeMets method. Tech Rpt #60, Dept of Statistics, Univ. of Wisconsin, 1992.
19. O'Brien P.C., Fleming T.R. A multiple testing procedure for clinical trials. Biometrics. 35:1979;549-556.
20. DeMets D.L., Ware J.H. Asymmetric group sequential boundaries for monitoring clinical trials. Biometrika. 69:1982;661-663.
21. Kim K., DeMets D.L. Design and analysis of group sequential tests based on the type I error spending rate function. Biometrika. 74:1987;149-154.
22. Bullard S.R., Donahue S.P., Feman S.S., Sinatra R.B., Walsh W.F. The decreasing incidence and severity of retinopathy of prematurity. J AAPOS. 3:1999;46-52.
23. Hussain N., Clive J., Bhandari V. Current incidence of retinopathy of prematurity, 1989-1997. Pediatrics. 104:1999;e26.
24. Reynolds J.D., Hardy R.J., Palmer E.A. Incidence and severity of retinopathy of prematurity. J AAPOS. 3:1999;321-322.
25. Spiegelhalter D.J., Freedman L.S., Blackburn P.R. Monitoring clinical trials. conditional or predictive power? Control Clin Trials. 7:1986;8-17.
26. Tsiatis A.A., Rosner G.L., Mehta C.R. Exact confidence intervals following a group sequential test. Biometrics. 40:1984;797-803.
27. Whitehead J., Stratton I. Group sequential clinical trials with triangular continuation regions. Biometrics. 39:1983;227-236.
28. Whitehead J. The design and analysis of sequential clinical trials. Rev. 2nd ed:1997;Wiley, Chichester.
29. Jennison C., Turnbull B.W. Group sequential methods with applications to clinical trials. 2000;Chapman Hall/CRC, Boca Raton.
30. Spiegelhalter D.J., Freedman L.S., Parmar M.K.B. Bayesian approaches to clinical trials. J R Stat Soc Ser A. 157:1994;357-416. [with discussion].
31. Grossman J., Parmar M.K.B., Spiegelhalter D.J., Freedman L.S. A unified method for monitoring and analyzing controlled trials. Stat Med. 13:1994;1815-1826.